2mg indications
MoA
MULTI-TARGETED MOA

See EYLEA® 2mg in action

DUAL-TRAP MECHANISM

STRONG

VEGF-binding affinity up to ~100-fold vs ranibizumab

 

BROAD

Unique multi-targeted trap is the only anti-VEGF that blocks all VEGFR-1 ligands, including VEGF and PGF,

 

LONG-LASTING

Delivers long-lasting anti-VEGF activity up to 2x longer than ranibizumab,,

 

 

In the treatment of DME,

even with complete VEGF blockade by ranibizumab or bevacizumab, PGF would still be available to bind VEGFR-1 allowing, for example, further escalation of inflammation in DME,,,

PP-EYL-IL-0128-1

    • 1
      Papadopoulos N, Martin J, Ruan Q,
      et al
      . Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15;171-185.
    • 2
      Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156:989-993.
    • 3
      Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100:1494-1498.
    • 4
      Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532-536.
    • 5
      Al Kahtani E, Xu Z, Al Rashead S,
      et al
      . Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye (Lond). 2017;31:529-536.
    • 6
      Nguyen QD, De Falco S, Behar-Cohen F,
      et al
      . Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 2018;e1-e9.
    • 7
      Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003;1:1356-1370.
    • a
      PGF only binds VEGFR-1.
    • b
      Bevacizumab has no marketing authorization for use in ophthalmic indications.